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ABSTRACT
Metastasis will continue to be an incurable disease for most patients until we 
develop highly selective anticancer therapies. The development of these therapies 
requires finding and exploiting major differences between cancer cells and normal 
cells. Although the sum of the many DNA alterations of cancer cells makes up such a 
major difference, there is currently no way of exploiting these alterations as a whole. 
Here I propose a non-pharmacological strategy to selectively kill any type of cancer 
cell, including cancer stem cells, by exploiting their complete set of DNA alterations. 
It is based on creating challenging environmental conditions that only cells with 
undamaged DNAs can overcome. Cell survival requires continuous protein synthesis, 
which in turn requires adequate levels of 20 amino acids (AAs). If we temporarily 
restrict specific AAs and keep high levels of others whose deficit triggers proteolysis, 
we will force cells to activate a variety of genetic programs to obtain adequate 
levels of each of the 20 proteinogenic AAs. Because cancer cells have an extremely 
altered DNA that has evolved under particular environmental conditions, they may 
be unable to activate the genetic programs required to adapt to and survive the new 
environment. Cancer patients may be successfully treated with a protein-free artificial 
diet in which the levels of specific AAs are manipulated. Practical considerations for 
testing and implementing this cheap and universal anticancer strategy are discussed.
INTRODUCTION
Pharmacotherapy is the standard of care for patients 
with metastasis. When the disease is spread and surgery 
and radiotherapy are no longer curative, drug therapy 
becomes the main form of treatment. Pharmacotherapy 
can prolong patients’ lives and palliate some disease-
related symptoms. However, it does not usually cure 
the disease. The low efficacy of the existing anticancer 
drugs is reflected in the poor survival rates of patients 
diagnosed with the most common metastatic cancers. The 
five-year relative survival rates for patients with distant 
metastasis are 4% in lung cancer, 28% in prostate cancer, 
25% in breast cancer, 13% in colorectal cancer, 16% in 
melanoma, 12% in renal cancer, 27% in ovarian cancer, 
18% in cancers of the uterine corpus, 16% in cancers of 
the uterine cervix, 6% in bladder cancer, 4% in esophageal 
cancer, 3% in liver cancer, and 2% in pancreatic cancer 
[1]. Many patients with metastasis do not overcome the 
disease despite surviving five years after diagnosis. 
Understanding why pharmacotherapy usually fails 
is important to develop better therapies. When one treats 
cancer cells with specific concentrations of approved 
anticancer drugs and examines the cells under the 
microscope, one generally observes a massacre. All cancer 
cells die in response to most treatments. However, these 
same drugs cannot save the lives of cancer patients. The 
main reason is that these drugs have a limited selectivity 
towards cancer cells. The consequence of this narrow 
selectivity is that patients cannot receive the drug doses 
required to kill all their cancer cells; such doses would 
also kill their normal body cells and would be lethal. As 
a poor alternative, they receive the maximum tolerated 
doses, which are usually insufficient to reach the drug 
concentrations required to eradicate their cancer cells. 
The surviving cancer cells continue to proliferate in an 
uncontrolled way until they eventually lead to a fatal 
outcome [2].
Research Perspective
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Pharmacotherapy also fails because some cancer 
cells are or become resistant to the drugs [3,4]. The 
most common reason for resistance is the expression of 
ATP-binding cassette (ABC) efflux transporters, which 
eject anticancer drugs from cells. These transporters 
are expressed in normal stem cells under physiological 
conditions; these cells have to remain intact for the entire 
life of an organism and need powerful defense mechanisms 
against environmental chemical insults. Recent evidence 
strongly suggests that cancer arises from normal stem 
cells [5-7]. After accumulating enough DNA alterations, 
normal stem cells give rise to cancer stem cells (CSCs) 
[5-7], which keep on expressing ABC transporters [8,9]. 
CSCs probably eject the drugs through these transporters 
and resist therapy. This suggests that even if we developed 
more selective anticancer drugs, mechanisms that have 
evolved to protect cells against chemical insults from 
the environment would continue to act as obstacles to 
successful treatment of cancer [3].
Cancer pharmacotherapy can also fail because 
most drugs preferentially target rapidly dividing cells. 
Resting and slow-proliferating cancer cells, such as CSCs, 
usually resist therapy. In addition, some resting and slow-
proliferating cancer cells are located in poorly vascularized 
tumor areas. Since the anticancer drugs are delivered to the 
cells through the blood, tumor cells located in these areas 
will be exposed to lower drug concentrations than normal 
cells (which have an adequate blood supply). This factor 
reduces the already limited selectivity of the existing 
anticancer drugs and contributes to therapy failure.
Improving the outcome of patients with metastasis 
requires the development of therapies with a high 
selectivity towards cancer cells. In addition, these therapies 
should overcome the drug-resistance mechanisms of these 
cells. They should also be effective against non-dividing 
cancer cells and poorly vascularized tumor cells. Here I 
describe a therapeutic strategy that may fulfill all these 
requirements.
Searching for selective anticancer therapies 
The main limitation of cancer pharmacotherapy is its 
low selectivity towards cancer cells. With the discovery of 
CSCs, it has often been assumed that the main limitation 
of the existing treatments is their inability to kill CSCs 
[10]. Evidence has accumulated that pharmacotherapy is 
ineffective at killing CSCs. However, this does not mean 
that the existing drugs can selectively kill the rest of 
cancer cells. As discussed elsewhere, the problem for most 
cancers is not that a few cancer cells survive treatment, but 
that only a few cancer cells die in response to treatment 
[11]. Successful cancer therapy requires the development 
of therapies with a high selectivity towards all types of 
cancer cells.
The basis for developing selective anticancer 
therapies is similar to that for developing selective anti-
infective treatments. The aim is to eliminate the infectious 
agent or the cancer cells without harming the patient too 
much. The way is to find major and exploitable differences 
between our cells and the infectious agent, or between 
our normal cells and the cancer cells. For example, 
unlike human cells, most bacteria have a cell wall. This 
major difference can be exploited by inhibiting cell wall 
synthesis with antibiotics such as penicillins. Because 
antibiotics can kill bacteria without significantly affecting 
human cells, they usually save the lives of people with 
bacterial infections. Saving the lives of patients with 
metastatic tumors requires finding major and exploitable 
differences between cancer cells and normal cells.
There exists a major difference between normal 
cells and all types of cancer cells: unlike normal cells, 
cancer cells have an extremely altered DNA. As explained 
elsewhere [12], if one looks at most tumor cells, it looks 
like someone set off a bomb in the nucleus. There are big 
pieces of chromosomes hooked together and gains and 
losses of whole chromosomes in most tumor cells [12,13]. 
The karyotype of some tumor cells is strikingly different 
from that of normal cells; for example, some studies have 
reported malignant cells with over 100 chromosomes 
(http://cgap.nci.nih.gov/Chromosomes/Mitelman). 
Within chromosomes, thousands of DNA mutations and 
epigenetic alterations are present in most tumors [14-16]. 
There are usually between 1,000 and 10,000 mutations in 
the genomes of most adult cancers, including breast and 
colorectal cancers. Some cancers carry fewer mutations 
(e.g., testicular germ cell tumors and some leukemias). 
Others, such as lung cancers and melanomas, have many 
more mutations (occasionally more than 100,000) [14]. 
It is actually surprising that cells with so many DNA 
alterations are able to survive.
Current therapies do not fully exploit this major 
difference between cancer cells and normal cells. The new 
drugs are usually designed to target single DNA defects of 
malignant cells. For example, cancer cells commonly have 
mutations in genes encoding particular protein kinases. 
Because these proteins play an important role in cancer 
cell proliferation, many of the drugs recently approved 
for cancer therapy have been designed to inhibit specific 
kinases. However, exploiting minor differences between 
cancer cells and normal cells usually leads to minor 
improvements in patient survival. It has been estimated 
that the recent approval of 71 anticancer drugs has only 
led to a median overall survival benefit of 2.1 months, 
balanced against an estimated 10,000 dollars per month on 
therapy at a cost of 2.7 million dollars per life year saved 
[17-20]. Current trends suggest that successful therapy of 
a particular cancer may require finding drugs for each of 
the driving mutations of that cancer. Given the complexity 
and variability of the cancer genome, the clinical benefit of 
this strategy may be limited [21,22].
The key to developing highly selective anticancer 
therapies probably lies on finding a way to exploit the 
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complete set of DNA alterations of cancer cells. Here I 
discuss that this can be achieved by creating a challenging 
cellular environment that only cells with undamaged 
DNAs can overcome. Normal cells would use their intact 
DNA to activate genetic and epigenetic programs to adapt 
to and survive the new conditions. Cancer cells, however, 
may be unable to survive in the new environment. The 
activation of these adaptation programs may require the 
expression of genes that, in cancer cells, may be lost, 
mutated or silenced. Some of these genes may be in 
chromosomes or pieces of chromosomes that were lost 
during carcinogenesis. Others may be mutated and non-
functional. In addition, the activation of a genetic or 
epigenetic program may require changes in other programs 
that cancer cells may need to keep unchanged for survival.
We can create a lethal environment for cancer cells 
without drugs. Because surgery and radiation therapy 
cannot eliminate non-localized tumor cells, we often 
assume that drug therapy is the only possible way to 
successfully treat patients with metastasis. By entering 
the bloodstream, a drug can potentially reach and kill any 
non-localized cancer cell. Although we can kill cancer 
cells by administering a cytotoxic agent, we can also kill 
them by restricting something they need to survive. The 
result seems to be the same; however, targeting cancer 
cells without drugs may overcome many drug-resistance 
mechanisms of cancer cells (e.g., there are no drugs to 
pump out of the cells through ABC transporters). In 
addition, the location of cancer cells in poorly vascularized 
tumor areas may not compromise the efficacy of a 
restriction therapy.
Selective killing of cancer cells by amino acid 
restriction
Cell survival requires protein synthesis. Proteins 
are continuously degraded and replaced with new ones to 
ensure a constant supply of functional proteins. The rate of 
turnover varies widely from protein to protein; the median 
has been estimated to be 0.5-35 hours in dividing cells 
and approximately 43 hours in non-dividing cells [23-25]. 
Protein synthesis in humans requires adequate levels of the 
20 canonical amino acids (AAs). An inadequate supply of 
just one of them for long enough will jeopardize protein 
synthesis and will result in cell death. Many proteinogenic 
AAs are also necessary for other cellular processes. All 
cancer cells, including CSCs, non-dividing cancer cells, 
or any type of resistant cancer cell, will die if they do not 
obtain adequate levels of any proteinogenic AA.
AA restriction can result in selective killing of 
cancer cells. Human cells cannot synthesize nine of the 
20 proteinogenic AAs; these nine AAs are referred to 
as essential AAs (EAAs) and need to be taken from the 
diet. The rest, called non-essential AAs (NEAAs), can be 
synthesized from glucose and from some essential and 
non-essential AAs. The biosynthesis of NEAAs requires 
a variety of enzymes that catalyze several reactions and 
pathways (Figure 1). Some genes encoding these enzymes 
may not be functional in cancer cells; they may be mutated, 
silenced or located in lost chromosomes. However, since 
dietary proteins provide each of the 20 AAs required 
for protein synthesis, these DNA alterations would not 
jeopardize the survival of cancer cells. This could change 
with a protein-free artificial diet in which the levels of 
particular NEAAs are temporarily restricted. Cancer cells 
with defects in the synthesis of a specific AA would not 
survive restriction of this AA, while normal cells would. 
This is supported by the clinical use of the anticancer 
drug asparaginase. It has been known for several decades 
that some leukemic cells have deficient expression of 
the enzyme asparagine synthase (ASNS), which results 
in deficient synthesis of the NEAA asparagine. Because 
normal cells can properly synthesize asparagine, its 
hydrolysis by asparaginase results in selective killing of 
leukemic cells [26]. Following asparagine restriction by 
asparaginase, normal cells synthesize this NEAA and 
survive, while leukemic cells do not synthesize it and die.
Amino acid restriction can also be lethal for cancer 
cells without mutations in genes involved in the synthesis 
of NEAAs. Carcinogenesis is an evolution process in 
which normal cells acquire multiple DNA alterations. 
However, not all of them provide a survival benefit. Since 
many DNA alterations are incompatible with cell survival 
under specific environmental conditions, cells can only 
acquire those alterations that allow them to survive in 
the existing environment. It is important to realize that 
carcinogenesis takes place under environments in which 
the levels and ratios of the 20 proteinogenic AAs remain 
relatively constant. The main reason is that virtually all 
food proteins contain each of the 20 proteinogenic AAs 
(gelatin lacks tryptophan), and a standard diet usually 
provides AAs at relatively constant ratios. However, 
we can alter the environment under which cancer cells 
have evolved with a protein-free artificial diet in which 
the levels of particular AAs are manipulated. This new 
environment may cause their death, because the DNA 
alterations that provide a survival benefit under specific 
environmental conditions may be lethal under other 
conditions. Scott et al. observed that over 90% of human 
cancer cells from a wide range of tumors and established 
cell lines died in vitro following arginine deprivation, 
while normal cells survived [27]. It is unlikely that all the 
susceptible cancer cells had mutations in genes involved 
in the synthesis of the NEAA arginine. Probably, arginine 
deprivation forced cells to activate a variety of genetic 
adaptation programs, which were functional in normal 
cells but not in cancer cells. The accumulation of DNA 
alterations in cancer cells during carcinogenesis probably 
inactivated the genetic programs required to adapt to and 
survive in the new environment created when arginine was 
deprived.
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Overcoming proteolysis by selective amino acid 
restriction
Restricting any AA in vitro is easy. One just has 
to prepare a medium without the desired AA and to add 
it to the cells. Restricting an AA in vivo is not that easy. 
The reason is that we have mechanisms for sensing 
and responding to AA deficiencies. Proteolysis is a 
key response mechanism to AA deprivation. Proteins 
are a source of AAs, and whole-body proteolysis and 
proteolysis at the cellular level can supply free AAs if their 
plasma or cellular levels are low. At the organism level, 
skeletal muscle proteolysis plays a key role in keeping 
adequate AA plasma concentrations during fasting periods. 
Liver proteolysis also plays a role. At the cellular level, 
protein breakdown during autophagy produces free AAs 
under conditions of AA limitation [28-31]. Some cancer 
cells, such as pancreatic cancer cells, are known to use 
macropinocytosis to transport extracellular proteins (e.g., 
albumin) into the cell. The internalized proteins undergo 
lysosomal degradation and produce free AAs [32,33]. 
This suggests that the dietary restriction of AAs will be 
buffered by the activation of proteolysis at the organism 
level and at the cellular level.
Although cells and organisms have mechanisms for 
sensing AA deficiencies, some of these mechanisms do not 
sense deficiencies in each of the 20 proteinogenic AAs. A 
sensing mechanism for each AA is not always necessary, 
mainly because they come together in the diet and because 
proteolysis provides all of them. During fasting, sensing 
one or several AAs may be sufficient to activate muscle 
proteolysis and elevate the levels of the 20 AAs. Evidence 
suggests that the levels of the EAA leucine may play a 
key role in controlling muscle protein metabolism; leucine 
supplementation stimulates muscle protein synthesis and 
Figure 1: Proteinogenic amino acids. The left part of the figure shows the proteinogenic amino acids and the main biosynthetic 
pathways for the non-essential amino acids (NEAAs). Selenocysteine [63] is not included for simplicity. The NEAAs are represented in 
blue and the essential amino acids (EAAs) in red. The right part of the figure provides links to the biosynthetic pathways, enzymes and 
amino acids. It also provides a link to their degradation pathways. The links provide useful information about the chromosome location 
of the genes coding for the enzymes, the tissue distribution of the enzymes, and the reactions known to produce and consume each amino 
acid. Most information was taken from HumanCyc: Encyclopedia of Human Genes and Metabolism (http://humancyc.org/). The interactive 
figure can be found in the Supplementary Figure1. Ser: L-serine; Cys: L-cysteine, Ala: L-alanine; Gly: glycine; Pro: L-proline; Glu: 
L-glutamate; Gln: L-glutamine; Asp: L-aspartate; Asn; L-asparagine; Arg; L-arginine; Met: L-methionine; Phe: L-phenylalanine; Leu: 
L-leucine; Ile: L-isoleucine; Val: L-valine; Lys: L-lysine; Thr: L-threonine; His: L-histidine; Trp: L-tryptophane.
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reduces muscle protein breakdown even when the levels 
of other AAs are decreased [34,35]. The levels of leucine 
required to inhibit muscle proteolysis seem to be higher 
than those for activating protein synthesis [36]. Leucine 
supplementation may therefore prevent muscle proteolysis 
during temporal restriction of specific AAs. Keeping an 
adequate cell volume in liver cells with sufficient levels of 
specific AAs, such as leucine and glutamine, may prevent 
liver proteolysis [28]. 
The mechanistic (or mammalian) target of 
rapamycin complex 1 (mTORC1) is a cellular nutrient 
sensor that plays a key role in the control of protein 
synthesis and degradation [30,37]. mTORC1 activity 
strictly depends on sufficient intracellular AA levels. AA 
restriction leads to mTORC1 inhibition, which in turn 
results in autophagy activation, lysosomal degradation of 
cellular proteins, and generation of free AAs. However, 
mTORC1 is not equally sensitive to all AAs; leucine, 
arginine and glutamine have been identified as key 
activators of mTORC1 [30,37,38]. Leucine is particularly 
important for its activation. Evidence suggests that 
leucyl-tRNA synthetase senses increased leucine levels 
and activates mTORC1 in order to suppress autophagy 
[39]. Supplementation of leucine may sustain mTORC1 
activity, thereby preventing autophagy-mediated 
proteolysis during temporal restriction of specific AAs. It 
has also been reported that glutamine activates the cellular 
uptake of leucine and can therefore facilitate leucine-
induced mTORC1 activation and autophagy inhibition 
[40]. Supplementation of sufficient levels of glutamine and 
leucine may prevent the activation of autophagy during 
AA restriction.
The general AA control non-derepressible 2 
(GCN2) kinase plays a key role in sensing deficits of any 
proteogenic AA [30,37]. Since no AA compensates for the 
absence of another during protein synthesis, GCN2 plays a 
key role in sensing low levels of each of the 20 proteogenic 
AAs. When an AA is scarce, its cognate aminoacyl transfer 
RNA synthetase fails to load the tRNA. The unloaded 
tRNA is detected by GCN2 kinase, which represses global 
protein synthesis by inhibiting the eukaryotic initiation 
factor 2α (eIF2α) kinase. At the same time, it activates 
the transcription of genes involved in the synthesis and 
cellular uptake of AAs in order to compensate the deficit. 
Although GCN2 allows for the detection of low levels of 
any proteinogenic AA in the context of an abundance of 
the other 19 AAs, it is important to realize that detecting 
the deficit is not sufficient to compensate it. The cell may 
need to activate genetic programs to obtain adequate levels 
of the restricted AA. These genetic programs may not be 
functional in cancer cells. In addition, the cells may need 
to move out of the cell cycle into a quiescent state until the 
deficit is overcome. Cancer cells may be unable to do so 
because of their DNA alterations.
Recent evidence supports a crosstalk between the 
GCN2-eIF2α and the mTORC1 signaling pathways to 
induce autophagy in response to nutrient deprivation [41]. 
This supports the possibility that GCN2 might detect 
restriction of any proteogenic AA and activate autophagy 
even in the presence of adequate levels of the rest of AAs. 
Even so, it is important to realize that cells cannot survive 
a prolonged restriction of any AA if they are unable to 
synthesize it or to obtain it from external sources. The 
continuous degradation of cellular components through 
autophagy will inevitably result in cell death.
Macropinocytosis of extracellular proteins in 
cancer cells may limit the efficacy of the anticancer 
strategy proposed in this manuscript. Macropinocytosis 
is a process in which extracellular fluid and its contents 
are internalized into cells through large vesicles known 
as macropinosomes. Some malignant cells, such as 
pancreatic cancer cells, can use macropinocytosis 
to transport extracellular proteins into the cell. The 
internalized proteins undergo lysosomal degradation and 
produce free AAs [32,33]. This suggests that a selective 
AA restriction therapy (SAART) may be ineffective 
for cancer cells taking extracellular proteins through 
macropinocytosis. However, recent data indicate that the 
utilization of extracellular proteins as a source of AAs is 
suppressed by mTORC1 [42]. Since mTORC1 activity 
depends on adequate intracellular levels of particular 
AAs, supplementation of these AAs may sustain mTORC1 
activity and prevent degradation of extracellular proteins. 
Alternatively, macropinocytosis can be selectively 
inhibited with Na+/H+ exchanger inhibitors such as 
amiloride (a diuretic drug) or 5-(N-Ethyl-N-isopropyl) 
amiloride [33,43]. 
CONCLUDING REMARKS
The anticancer strategy proposed in this manuscript 
consists of treating cancer patients with a protein-free 
artificial diet in which the levels of particular AAs are 
manipulated. Some AAs are eliminated or restricted. 
Others are increased or kept unchanged in relation to 
their normal intakes. The aim is to create a challenging 
AA imbalance, which will force cells to activate genetic 
programs to obtain adequate levels of the 20 proteinogenic 
AAs. Normal cells can use their functional genome to 
adapt to and resist this temporal challenging environment. 
Cancer cells, however, may be unable to do so. Their 
extremely altered DNA may compromise their ability to 
activate the genetic programs required to survive the new 
environment.
In vitro data have already shown that AA restriction 
can kill a wide range of cancer cells without affecting 
normal cells. For example, cells from a variety of tumors 
and established lines died quickly in vitro following 
arginine deprivation [27]. When normal cells and cancer 
cells were grown together in arginine-free medium, the 
normal cells survived while the cancer cells died [27]. 
Depriving cells of particular AAs in vivo is challenging, 
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because whole-body proteolysis can supply the AAs 
we restrict. However, experimental data indicate that 
proteolysis can be prevented when the levels of particular 
AAs are high. This suggests that we can create a 
challenging AA imbalance in vivo if we restrict specific 
AAs and keep high levels of others whose deficit triggers 
proteolysis. In fact, dietary deprivation of individual AAs 
for two weeks in mice resulted in significant alterations 
in the plasma levels of many proteinogenic AAs [44]. 
Restricting several AAs simultaneously, while increasing 
the levels of others, may lead to more marked AA 
imbalances.
It is difficult to predict at this time the most effective 
SAARTs, mainly because the mechanisms by which 
organisms and cells sense and respond to fluctuations in 
AA levels are far from been understood [30]. The good 
news is that there are only 20 proteinogenic AAs to 
manipulate. The possible combinations are finite, and their 
anticancer efficacy can be tested experimentally. Fully 
understanding how we sense and respond to AA restriction 
is not necessary to develop effective SAARTs. It would 
help, but it is not necessary.
Although none of the possible AA combinations 
should be ruled out, evidence suggests that some 
combinations may be more effective than others. Keeping 
high levels of leucine seems to be important to prevent 
whole-body and cellular proteolysis [30,34,35,37-39]. 
Keeping sufficient levels of glutamine, a common fuel 
for cancer cells [45], may also be important to prevent 
proteolysis [28,29,40]. Restricting NEAAs may be 
more effective than restricting EAAs. Neither normal 
cells nor cancer cells can synthesize EAAs. However, 
normal cells can synthesize NEAAs while cancer 
cells are probably unable to obtain all of them. This 
difference may confer selectivity. The idea is not to 
find the most toxic combination for cancer cells, but the 
most selective. Restricting several AAs together may 
be more effective than restricting AAs individually. 
Because the presence of some AAs can compensate 
for the deficit of others, it may be important to restrict 
complementary AAs simultaneously. For example, serine 
is required for the synthesis of cysteine, and serine and 
glycine are interconvertible through the enzymes serine 
hydroxymethyltransferases SHMT1 and SHMT2 (Figure 
1). Restricting these three NEAAs together may force 
cells to activate a variety of genetic programs, some of 
which may be inactivated in cancer cells. In fact, TP53 
gene (which encodes p53 protein) is the most frequently 
mutated gene in cancer, and evidence suggests that p53-
defficient tumors are vulnerable to serine starvation 
[46]. Rapidly proliferating cancer cells from a variety of 
tissues, but not rapidly proliferating normal cells, are also 
vulnerable to glycine deprivation [47]. Restricting cysteine 
may also be important to reduce the synthesis of the 
tripeptide glutathione (γ-L-glutamyl-L-cysteinylglycine); 
cancer cells may need high levels of the antioxidant 
glutathione to cope with the oxidative stress resulting from 
serine deprivation [46]. Reducing the levels of the EAA 
methionine (a precursor of cysteine) may increase the 
toxicity of this combination to cancer cells, but perhaps 
to normal cells too. Alternatively, if the restriction of 
serine, glycine and cysteine is enough to kill the cancer 
cells, increasing the levels of methionine may reduce 
the toxicity of this combination towards normal cells 
and make it more selective. Again, the key is not to find 
the most toxic combination for cancer cells, but to find 
a combination able to eliminate the cancer cells without 
significantly affecting our normal body cells.
Properly testing anticancer potential in vitro requires 
using cancer cells and a variety of nonmalignant cells 
[2,48,49]. The experimental approach used by Scott 
et al. [27] is adequate to detect the in vitro anticancer 
potential of any AA combination. However, restricting 
rather than depriving AAs may be more translatable to an 
in vivo situation. The information obtained in vitro will 
be valuable, but limited. Whole-body proteolysis is the 
main barrier to any SAART, and this parameter cannot be 
studied in vitro.
In vivo experiments may be necessary to properly 
screen the possible SAARTs. The following experimental 
approach could be used to screen these potential therapies 
easily, rapidly and reliably. First, inject cancer cells (e.g., 
mouse B16F10 melanoma cells) into the tail vein of 2-3 
mice (e.g., normal C57BL/6 mice) per group, and wait 
1-2 weeks so that lung metastases are fully established. 
Second, change their normal diet for a protein-free artificial 
diet in which the levels of particular AAs are manipulated; 
after a few days or weeks, change the artificial diet for 
the normal diet. Third, evaluate survival as an endpoint 
for efficacy assessment, that is, wait a few days or weeks 
to evaluate if the mice treated with the artificial diet live 
longer than the untreated mice. In the original protocols, 
the animals are euthanized 12-20 days after the tail vein 
injection, and each mouse usually has 200-300 pulmonary 
metastases when injected with 5 × 104 cells from a highly 
metastatic cell line (e.g., B16F10 melanoma cells) [50,51]. 
To my knowledge, current anticancer therapies cannot save 
the lives of these mice when treatments are started once 
the metastases are fully established. Untreated mice and 
mice treated with ineffective SAARTs will die quickly; 
results can be obtained fast. Effective treatments should 
be confirmed using more mice. The efficacy of a treatment 
should also be confirmed in additional metastatic models 
(e.g., metastatic xenograft models) using different types of 
cancer cells. Using human cancer cells from a variety of 
tissues and with different DNA alterations will help predict 
what cancer types are susceptible to a particular SAART. 
One should always have in mind that an experimental 
therapy should improve the survival of the standard 
treatment before advancing into clinical testing [49]. Any 
research team with cell culture and animal facilities can 
easily conduct these experiments. Unfortunately, my team 
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does not have funds to carry them out. 
When designing and testing possible SAARTs, 
it is essential to provide adequate nitrogen levels so 
that normal cells can synthesize the restricted NEAAs. 
A nitrogen-deficient diet will probably trigger whole-
body proteolysis. So, when we reduce the levels of some 
AAs, we should increase the levels of others or provide 
an alternative nitrogen source. Most proteinogenic AAs 
produce glutamate during their degradation, and glutamate 
provides the amino group for the synthesis of most NEAAs 
(Figure 1). This should facilitate the design of nitrogen-
balanced diets. It is also important to keep adequate levels 
of other nutrients, such as glucose and fatty acids, by 
supplying sufficient quantities of carbohydrates and fats. 
Deficits in these nutrients will probably trigger proteolysis. 
For example, hypoglycemia increases glucagon levels and 
triggers whole-body proteolysis, while hyperglycemia 
increases insulin levels and counteracts the proteolytic 
effect of glucagon [31,52,53]. If the artificial diet is 
hypocaloric, the cellular ATP:AMP ratios may decrease; 
this will activate autophagy even in the presence of 
adequate levels of AAs [30]. It should also be noted that 
animals and patients may reject artificial diets lacking 
particular AAs, especially diets lacking EAAs [54]. 
Cells in the brain’s anterior piriform cortex can sense AA 
deficiencies through the GCN2 kinase and signal food 
rejection [54]. Ensuring a sufficient intake of the artificial 
diet is important, because we need to keep high levels of 
the nutrients that prevent proteolysis.
The plasma half-life of the nutrients (or drugs) used 
to prevent proteolysis needs to be carefully considered to 
design the best administration protocols. For example, the 
increased levels of leucine achieved in blood after its oral 
administration do not last long [55]. This means that soon 
after the ingestion of an artificial diet rich in leucine, the 
body levels of this EAA may be insufficient of prevent 
whole-body proteolysis. The activation of proteolysis 
will increase the levels of the AAs we are restricting 
and will limit SAART efficacy. This limitation can be 
overcome by continuous feeding. In patients, this can 
be accomplished by continuous nasogastric feeding, or 
with a continuous intravenous infusion of an equivalent 
parenteral diet. Nasogastric feeding will probably result 
in higher concentrations of AAs in the liver, because 
nutrients absorbed from the gastrointestinal tract are 
delivered to the liver by the portal vein before reaching 
the general circulation (hepatic first-pass effect). Keeping 
high concentrations of AAs in the liver may be important 
to prevent liver proteolysis. Hepatic enzymes, however, 
may produce some of the restricted AAs and deliver them 
to the general circulation. 
Although SAART may be effective as a stand-
alone anticancer therapy, it may be necessary to combine 
it with drugs. If keeping high levels of particular AAs 
is not enough to prevent proteolysis sufficiently, insulin 
may be required to increase SAART efficacy. Insulin 
prevents whole-body proteolysis, especially muscle 
proteolysis [31]. Insulin also facilitates the cellular uptake 
of glucose and the activation of glycolysis. Because 
glycolysis provides ATP, this effect of insulin may be 
important to keep adequate cellular ATP:AMP ratios and 
thus avoid autophagy. In addition, glucose uptake and 
glycolysis are necessary to provide building blocks for the 
synthesis of NEAAs (Figure 1). Inhibitors of the Na+/H+-
exchanger may be needed to prevent macropinocytosis of 
extracellular proteins in some cancers [32,33,43]. Because 
sodium ions play a key role in AA transport across cell 
membranes [56], the use of Na+/H+-exchanger inhibitors 
(e.g., amiloride) and Na+/K+-ATPase inhibitors (e.g., 
cardiac glycosides) can alter AA transport across cell 
membranes and might help create an AA imbalance.
SAART may also be combined with standard 
anticancer treatments. For example, high levels of the 
tripeptide glutathione (GSH) confer resistance to a 
wide range of anticancer drugs [57-59], including the 
commonly used anticancer agent cisplatin [60]. Inhibitors 
of GSH synthesis and of GSH-dependent detoxifying 
enzymes have been developed [58,59]. These inhibitors 
increase the toxicity of many anticancer agents to cancer 
cells. However, these combinations induce toxicity to 
normal cells too. The reason is that normal cells also need 
GSH and GSH-dependent enzymes to protect themselves 
against these drugs and against the reactive oxygen 
species (e.g., hydrogen peroxide) produced during normal 
cell metabolism. As discussed before, restriction of the 
NEAAs cysteine, glycine and serine may compromise the 
synthesis of GSH in cancer cells, but not in normal cells. 
Normal cells would use GSH to detoxify the anticancer 
drugs and would survive. Cancer cells may be unable to 
do so and would die. Treatment of cancer patients with 
an adequate SAART (e.g., Cys-, Gly-, Ser-, Leu+, Gln+?, 
insulin+?) may selectively inhibit GSH synthesis in cancer 
cells. This may increase the selectivity of anticancer drugs 
such as cisplatin, which would result in improvements in 
the survival of cancer patients. 
It is becoming widely accepted that each cancer 
type, and even each cancer patient, may require a different 
therapy. The extensive mutational heterogeneity observed 
between and within tumors supports this view [17,61]. 
Evidence discussed in this manuscript indicates, however, 
that SAART may be effective against all types of cancer 
cells. All cells need to synthesize proteins, and all cancer 
cells have DNA alterations that may compromise their 
ability to obtain adequate levels of the 20 AAs required for 
protein synthesis. In addition, experimental and theoretical 
evidence suggests that specific SAARTs may be effective 
not only against all the cancer cells within a tumor, but 
also against a variety of tumor types. Experimental 
observations have revealed that every cancer cell within 
a tumor often contains the same core set of genetic 
alterations, with heterogeneity confined to mutations 
that emerge late during tumor growth [61,62]. The stem 
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cell division theory of cancer [5-7] can explain these 
experimental observations. If cancer arises from normal 
stem cells, all the mutations occurring in these cells before 
becoming malignant (CSCs) will be found in all their 
progeny, that is, in all the tumor cancer cells. Obviously, 
some tumor cells may lack some of these mutations if 
they lose during cell division the chromosomes or pieces 
of chromosomes that bear these DNA alterations. The 
mutations arising during the self-renewal of CSCs will be 
found only in the tumor populations derived from these 
malignant stem cells. In addition to self-renewing, CSCs 
generate progenitor cancer cells, which divide and produce 
the bulk of cancer cells within a tumor. The mutations 
found in few tumor cancer cells probably occur during the 
division of these progenitor cells. In some cases, the tumor 
cancer cells may arise from more than one normal stem 
cell. In these cases, not all the cancer cells within a tumor 
will share the same core set of genetic alterations. In short, 
experimental and theoretical evidence indicates that all 
the tumor cancer cells share the same core set of DNA 
alterations in most cases; therefore, all the tumor cells 
within a tumor may be vulnerable to the same SAART. 
Experimental data also suggest that different tumor types 
may be vulnerable to the same SAART. As discussed 
before, restriction of just one AA (i.e., arginine, serine 
or glycine) may be sufficient to kill many cancer cells 
of different tissues and genetic backgrounds [27,46,47]. 
Patients with different tumor types may therefore respond 
well to the same SAARTs. Naturally, this does not mean 
that all cancer patients will respond to the same SAART, or 
that all the cancer cells within a tumor will always respond 
to the same SAART. Sequencing different SAARTs should 
be considered when this occurs or to prevent this from 
happening.
SAART may also be used to prevent cancer, 
especially in people at high risk of developing the 
disease (e.g., aged people). SAART may be an effective 
strategy to selectively kill mutated stem cells before 
they give rise to cancer. Some mutations occurring early 
in carcinogenesis may confer sensitivity to particular 
SAARTs. For example, stem cells that develop mutations 
in the TP53 tumor suppressor gene may be vulnerable 
to serine restriction [46]. Although SAART may be a 
valuable preventive strategy, one should always keep 
in mind that the restriction of specific AAs (especially 
EAAs) may be highly toxic if proteolysis is inhibited. 
The possible toxicity associated with particular SAARTs 
should be carefully considered if they are to be used in 
healthy people.
Because all proteinogenic AAs are necessary for 
cell survival, our body should always provide an adequate 
supply of all of them if their dietary intake is low. 
However, evidence discussed in this manuscript indicates 
that our body will not sufficiently respond to deficits 
in specific AAs if the levels of other AAs and nutrients 
(e.g., glucose) are adequate. If proteolysis is sufficiently 
blocked by the presence of adequate levels of particular 
nutrients, a diet lacking specific proteinogenic AAs may 
cause cytotoxicity and may be fatal. This should not 
happen because our muscles store large quantities of all 
proteinogenic AAs. This possible biological flaw may be 
the key to successfully treating cancer.
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